CRIS Current Research Information System

PALLONI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.302
NA - Nord America 4.064
EU - Europa 2.574
AF - Africa 322
SA - Sud America 166
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.433
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.001
VN - Vietnam 1.177
SG - Singapore 1.130
CN - Cina 1.120
IT - Italia 715
GB - Regno Unito 344
SE - Svezia 336
DE - Germania 286
HK - Hong Kong 227
KR - Corea 182
IN - India 170
FR - Francia 148
NL - Olanda 138
IE - Irlanda 123
CH - Svizzera 117
FI - Finlandia 111
BR - Brasile 106
CI - Costa d'Avorio 106
RU - Federazione Russa 83
SC - Seychelles 65
JP - Giappone 52
NG - Nigeria 50
ZA - Sudafrica 43
TG - Togo 40
CA - Canada 35
PH - Filippine 32
ID - Indonesia 29
JO - Giordania 27
AT - Austria 26
BG - Bulgaria 21
TR - Turchia 21
GR - Grecia 20
IQ - Iraq 20
AR - Argentina 18
EE - Estonia 18
MX - Messico 17
BD - Bangladesh 16
TW - Taiwan 16
UA - Ucraina 16
BE - Belgio 15
PK - Pakistan 15
PL - Polonia 15
TH - Thailandia 14
CL - Cile 11
PS - Palestinian Territory 11
SA - Arabia Saudita 10
ES - Italia 9
LT - Lituania 9
EC - Ecuador 8
PY - Paraguay 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
MA - Marocco 5
MY - Malesia 5
PT - Portogallo 5
UZ - Uzbekistan 5
CO - Colombia 4
CR - Costa Rica 4
DZ - Algeria 4
NI - Nicaragua 4
PE - Perù 4
RO - Romania 4
BO - Bolivia 3
DK - Danimarca 3
IR - Iran 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
CZ - Repubblica Ceca 2
EG - Egitto 2
HU - Ungheria 2
KZ - Kazakistan 2
LB - Libano 2
NP - Nepal 2
RS - Serbia 2
SI - Slovenia 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
CG - Congo 1
ET - Etiopia 1
GE - Georgia 1
GN - Guinea 1
HT - Haiti 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MD - Moldavia 1
MM - Myanmar 1
MT - Malta 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PA - Panama 1
SK - Slovacchia (Repubblica Slovacca) 1
TV - Tuvalu 1
Totale 11.433
Salva come PNG Salva come JPEG
Città #
Singapore 814
Dallas 682
Ashburn 440
Hefei 398
Chandler 318
Ho Chi Minh City 273
Southend 267
Hanoi 254
San Jose 228
Fairfield 224
Hong Kong 213
Seoul 160
Bologna 149
Houston 129
Santa Clara 127
Dong Ket 126
Dublin 123
Beijing 120
Bern 107
Abidjan 106
Princeton 100
Wilmington 92
Helsinki 89
Seattle 89
Woodbridge 86
Boardman 80
New York 75
Council Bluffs 66
Rome 66
Lauterbourg 65
Cambridge 64
Los Angeles 61
Frankfurt am Main 59
Ann Arbor 57
Tokyo 43
Lomé 40
Milan 40
Da Nang 38
Bengaluru 35
Turin 33
Berlin 32
Redmond 32
Haiphong 30
Nanjing 29
Redondo Beach 28
Buffalo 27
Amman 26
Westminster 25
Abeokuta 24
London 24
Tongling 24
Munich 22
Sofia 21
Shanghai 19
Jakarta 18
Lappeenranta 18
Florence 17
Jinan 16
Johannesburg 16
San Diego 16
Biên Hòa 15
Hải Dương 15
São Paulo 15
Amsterdam 14
Guangzhou 14
Padova 14
Toronto 14
Medford 13
Nuremberg 13
Ravenna 13
Brussels 12
Can Tho 12
Hyderabad 12
Orem 12
Bến Tre 11
Shenyang 11
Thái Nguyên 11
Vienna 11
Brooklyn 10
Chicago 10
Denver 10
Des Moines 10
Groningen 10
Istanbul 10
Montreal 10
Olalla 10
Warsaw 10
Baghdad 9
Chennai 9
Falkenstein 9
Halhul 9
Phoenix 9
Stockholm 9
Tianjin 9
Wuhan 9
Wuxi 9
Bắc Ninh 8
Shenzhen 8
The Dalles 8
Yubileyny 8
Totale 7.435
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 451
Adjuvant treatment in biliary tract cancer 341
D32Left versus right side primary tumor: the correlation with clinical outcome of patients with resected stage II and III colorectal cancer 307
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 301
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 296
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone 276
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 245
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 238
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 230
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 225
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 216
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 216
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 209
TERC and c-MYC COPY number gain in intraductal papillary mucinous neoplasms (IPMNs): promising biomarkers of progression to malignancy 209
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 207
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 207
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 204
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 200
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 198
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 197
Bone metastases in biliary cancers: A multicenter retrospective survey 197
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 197
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 195
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 194
TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS 190
Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 189
In Reply 188
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 184
Discovery of new potential actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 183
Searching for novel multimodal treatments in oligometastatic pancreatic cancer 178
State of the art biological therapies in pancreatic cancer 177
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 176
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. 175
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 175
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 171
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 171
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 164
Chemotherapy in Patients with Advanced Cholangiocarcinoma 162
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 157
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 157
Hacking pancreatic cancer: Present and future of personalized medicine 157
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 156
Decreasing Albumin mRNA Expression in Cholangiocarcinomas along the Bile Duct Tree. 149
Chemoradiation of locally advanced biliary cancer: A PRISMA-compliant systematic review 148
Radiotherapy or chemoradiation in unresectable biliary cancer: A retrospective study 144
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 140
Classic versus innovative strategies for immuno-therapy in pancreatic cancer 133
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue 130
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 130
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 127
Experimental HER2- targeted therapies for biliary tract cancer 127
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 125
The use of comprehensive complication Index® in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center 122
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 118
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 118
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma 117
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 106
Should we incorporate ablative radiotherapy in standard treatment of advanced intrahepatic cholangiocarcinoma? 104
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 102
Nivolumab: an investigational agent for the treatment of biliary tract cancer 101
Prognostic value of integrated morphofunctional imaging methods in inoperable intrahepatic cholangiocarcinoma 98
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab 94
The use of comprehensive complication Index® in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center 80
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 78
Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma 61
Concurrent Chemoradiation Outperforms Chemotherapy Alone in the Treatment of Unresectable Biliary Tract Cancers: A Meta-analysis. 59
Does Adjuvant Therapy in Invasive Intraductal Papillary Mucinous Neoplasm of the Pancreas Improve Survival? A Systematic Review and Meta‐Analysis Using Trial Sequential Analysis 39
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab 33
Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma 27
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study 25
Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma 22
Totale 11.723
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.291
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.291
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021283 0 0 0 0 0 0 0 0 0 34 37 212
2021/20221.067 68 37 43 75 70 34 26 73 135 113 236 157
2022/20231.407 125 203 71 141 101 101 45 83 224 64 92 157
2023/2024471 76 55 32 42 37 81 20 27 15 37 28 21
2024/20251.888 100 200 163 119 169 73 114 123 61 186 173 407
2025/20265.330 530 626 992 422 475 238 517 197 991 342 0 0
Totale 11.723